Related Experiment Video
Updated: Jun 2, 2026

Isolation of Primary Mouse Hepatocytes for Nascent Protein Synthesis Analysis by Non-radioactive L-azidohomoalanine Labeling Method
Published on: October 23, 2018
Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2
Morris E Feldman1, Beth Apsel, Aino Uotila
1Howard Hughes Medical Institute and Department of Cellular and Molecular Pharmacology, University of California San Francisco, San Francisco, USA.
Abstract:
The mammalian target of rapamycin (mTOR) regulates cell growth and survival by integrating nutrient and hormonal signals. These signaling functions are distributed between at least two distinct mTOR protein complexes: mTORC1 and mTORC2. mTORC1 is sensitive to the selective inhibitor rapamycin and activated by growth factor stimulation via the canonical phosphoinositide 3-kinase (PI3K)-->Akt-->mTOR pathway. Activated mTORC1 kinase up-regulates protein synthesis by phosphorylating key regulators of mRNA translation. By contrast, mTORC2 is resistant to rapamycin. Genetic studies have suggested that mTORC2 may phosphorylate Akt at S473, one of two phosphorylation sites required for Akt activation; this has been controversial, in part because RNA interference and gene knockouts produce distinct Akt phospho-isoforms. The central role of mTOR in controlling key cellular growth and survival pathways has sparked interest in discovering mTOR inhibitors that bind to the ATP site and therefore target both mTORC2 and mTORC1. We investigated mTOR signaling in cells and animals with two novel and specific mTOR kinase domain inhibitors (TORKinibs). Unlike rapamycin, these TORKinibs (PP242 and PP30) inhibit mTORC2, and we use them to show that pharmacological inhibition of mTOR blocks the phosphorylation of Akt at S473 and prevents its full activation. Furthermore, we show that TORKinibs inhibit proliferation of primary cells more completely than rapamycin. Surprisingly, we find that mTORC2 is not the basis for this enhanced activity, and we show that the TORKinib PP242 is a more effective mTORC1 inhibitor than rapamycin. Importantly, at the molecular level, PP242 inhibits cap-dependent translation under conditions in which rapamycin has no effect. Our findings identify new functional features of mTORC1 that are resistant to rapamycin but are effectively targeted by TORKinibs. These potent new pharmacological agents complement rapamycin in the study of mTOR and its role in normal physiology and human disease.
Insights
Novel mTOR inhibitors called TORKinibs target both mTORC1 and mTORC2 complexes, offering enhanced inhibition of cell growth and protein synthesis compared to rapamycin. These compounds reveal new rapamycin-resistant functions of mTORC1.
Area of Science:
- Cellular Biology
- Molecular Biology
- Pharmacology
Background:
- The mammalian target of rapamycin (mTOR) pathway is crucial for regulating cell growth, survival, and metabolism.
- mTOR functions through two distinct complexes, mTORC1 and mTORC2, with differential sensitivity to inhibitors like rapamycin.
- Current rapamycin-based therapies primarily target mTORC1, leaving mTORC2 effects less understood.
Purpose of the Study:
- To investigate the effects of novel ATP-competitive mTOR kinase inhibitors (TORKinibs) on both mTORC1 and mTORC2.
- To compare the efficacy of TORKinibs with rapamycin in inhibiting cell proliferation and key signaling pathways.
- To elucidate new functional aspects of mTORC1 activity resistant to rapamycin.
Main Methods:
- Utilized novel mTOR kinase domain inhibitors (TORKinibs PP242 and PP30) in cellular and animal models.
- Assessed the phosphorylation status of Akt (a key downstream target) at specific sites (S473 and T308).
- Measured protein synthesis rates, focusing on cap-dependent translation, and cell proliferation.
Main Results:
- TORKinibs effectively inhibited both mTORC1 and mTORC2, leading to decreased Akt phosphorylation at S473 and reduced overall Akt activation.
- TORKinibs demonstrated superior inhibition of primary cell proliferation compared to rapamycin.
- PP242 showed enhanced mTORC1 inhibition and blocked cap-dependent translation more effectively than rapamycin.
Conclusions:
- Novel TORKinibs provide potent inhibition of both mTORC1 and mTORC2, surpassing rapamycin's efficacy.
- These inhibitors reveal previously uncharacterized rapamycin-resistant mTORC1 functions, particularly in regulating cap-dependent translation.
- TORKinibs represent valuable pharmacological tools for studying mTOR signaling in physiology and disease, offering a complementary approach to rapamycin.
Related Concept Videos
Inhibition of Cdk Activity
Abnormal Proliferation
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
The JAK-STAT Signaling Pathway
PI3K/mTOR/AKT Signaling Pathway
mTOR Signaling and Cancer Progression
The mTOR pathway or the...

